Pfizer will be distributing half of the original 100 million COVID-19 vaccines that they promised by the end of 2020.
Due to supply chain issues, the drug company confirmed they will be delivering up to 50 million doses of the vaccine globally by the end of the year, down from the 100 million doses that it had previously promised.
A spokesperson from Pfizer told Daily Hive in a written response there are several factors that have impacted the number of COVID-19 vaccine doses estimated to be available by the end of the year.
“Scaling up a vaccine at this pace is unprecedented, and we have made significant progress as we have moved forward in the unknown,” said the spokesperson. “Additionally, the scale up of the raw material supply chain took longer than expected.”
View this post on Instagram
“It is important to highlight that the outcome of the clinical trial was somewhat later than the initial projection, requiring us to focus additional efforts on clinical trial production. Please note that modifications to our full-scale production lines in the US and Europe are now complete and finished doses are being made at a rapid pace.”
Based on current projections, Pfizer says that it expects to produce up to 50 million vaccine doses globally in 2020, and is confident in supplying approximately 1.3 billion doses by the end of 2021.
In November, Pfizer adjusted their projection to say it would have up to 50 million doses prepared to be distributed globally by the end of 2020, but had previously promised up to 100 million doses as late as September.
The United Kingdom was the first country that would approve the vaccine on Wednesday.